Mobile applications for people with MS
In addition to their current digital channels, Sanofi Genzyme wished to develop Mobile Applications for people in Europe, the Middle East and Africa with MS who have been prescribed with the medications AUBAGIO® and LEMTRADA®.
LEMCHECK app supports self-monitoring of MS patients
The medicine LEMTRADA® (alemtuzumab) is indicated for the treatment of patients with relapsing remitting MS (RRMS). Patients treated with LEMTRADA® need monthly monitoring until 48 months after the last treatment course.
The LEMCHECK™ app, among other objectives, serves to support the adherence of these patients during the self-monitoring activities.
The LEMCHECK™ apps help patients to:
- comply with monthly tests
- plan self-check activities
- log findings
- share findings with their physician
- identify and report symptoms
- have better understanding over their treatment